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ANAPLASTIC MENINGIOMA
Case report
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ABSTRACT - Intracranial meningiomas continue to challenge our best clinical efforts to eliminate them once
discovered and deemed appropriate for treatment. Malignant meningiomas constitute 10% to 15% of all
meningiomas and limited information exists regarding adjuvant treatment. The external whole brain irradiation
is recommended. Traditional chemotherapy has proven ineffective; thus, new chemotherapeutic agents and
new methods of delivery should be developed. Immunotherapy may be considered for patients with malignant
meningiomas when all others previous treatment have failed. We report a case of anaplastic papillary
meningioma. A 67-year-old man presented with partial complex seizures, headache and aggressiveness. A
computerized tomography and magnetic resonance image demonstrated a large left temporo-occipital mass
with difuse contrast enhancement and extensive surrounding edema. A left temporo-occipital flap was
performed. The tumor and the infiltrated dura were radically removed. Postoperatively, the patient remained
neurologically intact. The treatment was complemented by external whole brain radiation.
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Meningioma anaplásico: relato de caso
RESUMO – O tratamento adequado para os pacientes com meningiomas intracranianos continua sendo um
desafio, principalmente o de sua variante maligna, a qual tem incidência de 10% a 15%, sem uma certeza do
melhor tratamento adjuvante. É indicado o uso da radioterapia externa holocraniana. O uso da quimioterapia
tradicional se mostra ineficaz, havendo necessidade de estudos para desenvolver outros agentes quimioterápicos
e novos métodos de administração desses agentes no tumor cerebral. A imunoterapia pode ser considerada
para os casos de refratariedade aos outros tratamentos adjuvantes. Relatamos o caso de um paciente de 67
anos, com história progressiva de cefaléia, crises convulsivas parciais complexas e agressividade. A investigação
radiológica com tomografia computadorizada e ressonância magnética evidenciaram um processo expansivo
na região temporoccipital esquerda com contrastação difusa e edema peritumoral importante. Foi realizada
craniotomia frontoparietotemporal esquerda com remoção radical da dura-máter infiltrada e do tumor. O
paciente evoluiu sem déficit neurológico no pós-operatório. O exame anatomopatológico foi compatível com
meningioma maligno do tipo papilar. Foi instituído tratamento complementar com radioterapia externa
holocraniana.
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Meningioma, one of the most common types of
brain tumors in adults, remains a clinical problem
yet to be solved by neurologist, neurosurgeons and
oncologists. Meningiomas constitute 15% to 20%
of all primary brain tumor and 10% to 15% of all me-
ningioma are considered malignant1,2 . These tumors
will recur after standard therapies of surgical exci-
sion, radiation therapy, radiosurgical techniques, and
chemotherapy1,3-6.
We report a case of papillary meningioma, con-
sidered be analastic, and the literature is reviewed.
CASE
This 67-year-old man presented with strong headache,
behavior disorder, vomiting and two episodes of partial
complex seizures in the last three months. The neurologi-
cal examination revealed a mild mental confusion and bi-
lateral papilledema. There was no motor or sensitive signs
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Fig 1. MRI in coronal (A), sagittal (B) and transversal (C) view obtained with contrast agent showed an enhancing tumor in left temporo-
occipital lobe and a transtentorial herniation.
Fig 2. Postoperative MRI in transversal (A) and sagittal (B) view showed a radical tumor removal.
Fig 3. Photomicrographs illustrating histological features. H&E. Left - Malignant meningioma showing vascular
channels surrounded by neoplastic meningothelial cells with a papilliferous aspect. Original magnification, X100.
Right - Highly cellular areas with mitotic figures. Original magnification, X400.
or symptoms. A computerized tomography (CT) scan of head
with contrast demonstrated a large left temporo-occipi-
tal mass, diffuse contrast enhancement and some small
hypodense areas located at anteromesial portion. A mag-
netic resonance image (MRI) obtained with and without
contrast showed an enhancing lesion in the left temporal
and occipital lobe with extensive surrounding edema and
a transtentorial herniation (Fig 1). The left tentorium and
the dura adjacent to the lesion were strongly enhancing.
A left temporo-occipital flap was performed. There were
some areas of clear cut between the normal brain tissue
and the tumor. But on other areas these limits could not
be so evident. The tumor was strongly vascularized. The
dura infiltrated by the tumor was removed. The tumor
was removed radically and it can see at the postoperative
MRI scans (Fig 2). Postoperatively, the patient remained
neurologically intact. He stayed at ICU for 48 hours with
intracranial pressure monitoring within normal values at
all. There were no complications and the patient was dis-
charged at one week. The patient was referred to radio-
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therapy unit to receive complementary treatment with ex-
ternal whole brain radiation. The histopathologic exam sho-
wed malignant meningioma with vascular channels surro-
unded by neoplastic meningothelial cells with a papillifer-
ous aspect and highly cellular areas with mitoses (Fig 3).
DISCUSSION
Malignant meningiomas represent 10% to 15%
of all meningiomas1. The peak incidence of atypical
and malignant meningioma was in the seventh and
sixth decades, respectively7. These malignant men-
ingiomas are defined by several criteria including:
1) invasion of adjacent brain parenchyma or skull;
2) numerous mitoses (> 5/high-powered field); 3) ele-
vated proliferative index (>3%) as assessed by ei-
ther 5-bromodeoxyuridine or KI-67 staining; 4) ne-
crosis; 5) increased cellularity; 6) nuclear pleomor-
phism; and 7) metastasis1,5,8-12.
The cell origin of the meningiomas is the arach-
noid cap cell, which has a slow rate of cell division.
Although tumors originating from the meninges are
typically benign, they occasionally behave in an ag-
gressive fashion and carry a much poorer prognosis
than do benign meningiomas1,3-6. Tumorigenesis
must be the result of exogenous or endogenous fac-
tors acting alone or together. Exogenous factors in-
clude trauma, viral infection, and prior brain irradia-
tion. Endogenous stimulation can occur through the
action of hormones or growth factors.
There was a clear tendency toward a progressively
higher frequency of malignant meningiomas among
recurrent tumor13. Malignant meningiomas were
tumors that had undergone reoperation and had ori-
ginally been either benign or aggressive meningioma.
This suggests a likelihood that any benign tumor that
recurs will be malignant1,6. Whereas benign menin-
giomas tend to show preponderance in females,
atypical and malignant meningiomas have a male
preponderance12,14 .
Pathology
Cushing coined the term “meningioma” to de-
scribe this tumor attached to the meninges. Since
that time, a number of histopathologic schemes have
been presented. Currently the WHO-II classifications
of meningiomas are the most used. This histological
classification system divides tumors of meningo-
thelial cells into four groups: classic, atypical, papil-
lary and anaplastic. These classifications can be
complemented with the Helsinki grading system15.
This grading system assigns points from 0-3 for six
pathological features: loss of architecture, increased
cellularity, nuclear pleomorphism, mitotic figures,
focal necrosis, and brain infiltration. The sum of these
points is then used to describe the benign, atypical,
anaplastic and sarcomatous forms of meningiomas.
The proliferative potential of tumors can be quanti-
tated, using bromodeoxyuridine, KI-67, MIB-1 and
proliferating cell nuclear antigen (PCNA) labeling
index, and this information helps in predicting the
clinical behavior of tumors and the need for treat-
ment1,12.
Palma et al.6 defined the differences between atypi-
cal (42 cases) and malignant (29 cases) meningio-
mas by the World Health Organization and studied
the influence on prognostic: survival at 5 and 10 years
was obtained in 95% and 79%, respectively, of pa-
tients with atypical meningioma and in 64.3% and
34.5% of patients with malignant meningioma; re-
currence-free survival was 11.9 years in patients with
atypical meningioma and 2 years with malignant
meningioma; the authors concluded that radical ex-
tirpation and histological findings were significantly
related to prolonged survival.
Radiological Features
Servo et al.16 and Younis et al.12 determined that
CT cannot reliably distinguish malignant meningio-
mas from benign ones. There are, however, some CT
or MRI trends that point in favor of malignant men-
ingioma: 1) the absence of visible calcium aggre-
gates12; 2) “mushrooming” or the presence of a
prominent pannus of tumor extending well away
from the globoid mass7,10,12; 3) nonhomogeneous
enhancement10; 4) necrosis10; and 5) presence of in-
distinct tumor margins7,12,16. If angiography is per-
formed, arteriovenous shunting is a feature that sug-
gests malignancy1.
Marked peritumoral edema, osteolysis, intrinsic
cystlike areas and tumor density have a controver-
sial radiological feature in relation to malignancy12,16.
Elster et al.17 could not detect any significant differ-
ence on either T1-weighted or T2-weighted studies
which allowed differentiation of malignant from
benign meningiomas.
Surgery
Surgery remains an important part of treatment
of malignant meningiomas. Over the past several
years, advances in surgical technique and a revisit-
ing of surgical anatomy have prompted more agres-
942 Arq Neuropsiquiatr 2001;59(4)
sive approaches to brain tumors. Despite the gross-
total tumor ressection, the survival of malignant me-
ningiomas without adjuvant therapy is less than 2
years1,5,8-11,18. In patients with malignant meningio-
mas treated with surgery and adjuvant therapy (ei-
ther radiation alone or radiation plus chemotherapy),
median survival time was 5 years and the degree of
tumor resection did not predict recurrence14.
Chen & Liu4 reported that a recorrence rate with
a median follow-up of 3 years after surgery was 44%
for atypical or anaplastic meningioma and 6% for
benign meningiomas. Younis et al.12 reported that
recurrence and survival time was shorter in patients
with malignant meningiomas who had received par-
tial resection on first presentation of tumor than in
those who underwent total resection; in their series
the patient’s prognoses did not improve as a result
of either chemotherapy or radiotherapy.
Dziuk et al.13 reported a disease free/progression
free survival at 5 years was 39% following total re-
section versus 0% after subtotal resection (p=0.001)
in patient with malignant meningioma; they stated
that complete surgical resection is crucial for long-
term control.
Malignant meningiomas located at the parasellar
region and the posterior fossa a conservative removal
of tumor followed by irradiation is advocated in pref-
erence to a radical operation that may cause neuro-
logical injury without being curative1.
Radiation Therapy
The value of fracionated external beam radiation
therapy or steriotactic radiosurgery in improving
tumor control and survival for patients with subto-
tally resected, recurrent and malignant meningio-
mas is confirmed1,2,5,8,10,11,19,20.
Goldsmith et al.21 showed that the 5-year pro-
gression-free survival rate after subtotal resection
and radiation therapy was 89% for benign menin-
giomas and only 48% for malignant meningiomas;
an improved progression-free survival rate was re-
lated with a younger age and treatment after 1980
with innovative technologies, none of these variables
affected the progression-free survival rate in the pa-
tients with malignant meningioma.
Milosevic at al.22 reported 59 patients with atypi-
cal or malignant meningiomas treated during the
period of 1966 and 1990; the 5-year overall and
cause-specific survivals after surgery and radiothe-
rapy were 28 and 34%, respectively; age less than
58 years, treatment after the year 1975 and a radia-
tion dose greater than or equal to 50 GY were asso-
ciated with improved cause-specific survival; the au-
thors recommended that all patients with atypical
or malignant meningiomas receive radiation therapy
immediately after surgery.
Rodriguez et al.18 analyzed 35 patients with ma-
lignant meningioma, of whom 15 (43%) were treated
with surgery alone, 12 (34%) with surgery plus ra-
diotherapy, six (17%) with surgery plus radiotherapy
and chemotherapy, and two (6%) with no further
treatment: the 3-year recurrence probability was 27%
for patients who received adjuvant radiotherapy ver-
sus 69% for patients treated solely with surgical re-
section; the 5-year survival rate was estimated at
64%. Sixty-seven patients experienced recurrence at
5 years.
According Dziuk et al.13 adjuvant irradiation fol-
lowing initial resection increased the 5-years disease
free survival rates from 15% to 80% (p=0.002); when
administered for recurrent lesions, adjuvant radiothe-
rapy improved the 2-years disease free survival from
50% to 89% (p=0.015), but had no impact on 5-years
disease free survival; the authors concluded that ex-
tent of resection, adjuvant radiotherapy, and recur-
rence status are independent prognostic factors.
Kondziolka et al.19 treated 50 patients with men-
ingiomas using the 201-source cobalt-60 gamma
knife with a follow-up of 30-month; the authors con-
cluded that radiosurgery was an effective primary
treatment alternative for patients with advanced age,
medical condition, or high-risk tumor location.
Interstitial brachytherapy has been used to the
treatment of malignant meningiomas after standard
therapies have failed23,24. Rogano et al.23 reported
their experience with iodine-125 sources placed at
open operation for 22 patients with recurrent or
malignant meningiomas obtained a 96 weeks of the
median time to tumor progression and a 124 weeks
of the median survival from the time of implanta-
tion; 38% of their patients had complications related
to therapy; the authors conclude that interstitial
brachytherapy remains an option for tumor volumes,
shapes, and locations not amenable to stereotactic
techniques.
Chemotherapy
The role of cytotoxic chemotherapy in the man-
agement of recurrent or malignant meningiomas has
not fully investigated. The value of adjuvant chemo-
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therapy is not clear giving the confounding and prob-
ably more beneficial effects of adjuvant radiotherapy
also administered to these patients14.
Wilson1 reported 11 cases with recurrent malig-
nant meningiomas treated with surgery, radio-
therapy and chemotherapy using ciclophosphamida,
doxorubicin and vincristine with 73% progressed at
1 year and 100% at 2 years.
Stewart et al.25 use intra-arterial cis-platinum and
intravenous doxorubicin for inoperable recurrent
meningiomas with a response in one case and tu-
mor control in the other case.
Chamberlain14 reported the use of cyclophospha-
mide, adriamycin and vincristine after external beam
radiation therapy for up to six cycles of treatment
for 14 cases of malignant meningiomas. Patients who
had gross total resection only received three cycles
of chemotherapy; the median time to tumor pro-
gression was 4.6 years and the median survival was
5.3 years; the author concluded that these combined
modality therapies is associated with acceptable tox-
icity and a modest improvement in survival when
compared to patients treated with surgery alone.
Younis et al.12 reported 10 patients with aggres-
sive meningeal tumors who received intra-arterial or
intravenous cis-platinum, intravenous dacarbazine
and intravenous doxorubicin; clinical improvement
or radiologic tumor response related to chemo-
therapy could not be observed.
Rodriguez et al.18 treated six patients with malig-
nant meningioma with surgery plus radiotherapy and
chemotherapy with free of recurrence at a median
follow-up period of 4 years. The initial encouraging
results on long-term oral therapy of 14 cases of un-
resectable meningiomas with the antiprogesterone
mifepristone (RU486) remain to be proven in a larger
cohort of patients26.
Immunotherapy
Immunotherapy may be considered for malignant
meningiomas when all others previous treatment
have failed. The most effective immunotherapy ap-
pears to be administration of interferon-alpha, which
is relatively non-toxic and easily tolerated27,28. More
studies are needed to better define the roles of these
agents in the treatment of malignant meningiomas.
In conclusion, an aggressive treatment approach
with radical surgery and postoperative radiotherapy
is warranted in patients with these tumors. Tradi-
tional chemotherapy has proved innefective and the
role of adjuvant immunotherapy, brachytherapy or
radiosurgery are unknow. Because malignant men-
ingiomas are uncommon tumors, a cooperative
group study would be required to assess covariants.
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